Ligand ID: CTC


Drugbank ID:
DB09093
(Chlortetracycline)


Indication:
Chlortetracycline is a tetracycline antibiotic, the first tetracycline to be identified. It was discovered in 1945 by Benjamin Minge Duggar working at Lederle Laboratories under the supervision of Yellapragada Subbarow. Duggar identified the antibiotic as the product of an actinomycete he cultured from a soil sample collected from Sanborn Field at the University of Missouri. The organism was named Streptomyces aureofaciens and the isolated drug, Aureomycin, because of their golden color.

Get human targets for CTC in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'CTC'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		1uk2 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
HIS A 172
PHE A 140
THR A 135
LEU A 177
SER A 147
1.67A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		1uk2 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ASN B 119
GLN B  19
GLY B 120
SER B 144
GLY B  23
1.78A23.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		1x7q BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 12
SER B  28
PHE B  62
HIS B  31
ILE B  35
SER B  33
1.78A20.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
GLN B1306
MET A  17
ASN A 119
GLY A  71
GLY A 124
1.65A23.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASN F  27
THR A  21
GLN A  17
ILE A  13
SER F  29
1.74A10.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		2ajf ACE2
(Homo
sapiens)		4 / 8
GLN B 524
PHE B 525
GLY B 399
MET B 557
1.40A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2ajf ACE2
SPIKE PROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 460
HIS F 445
THR B  20
GLN B  24
SER F 461
1.73A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		2ajf ACE2
SPIKE PROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 460
HIS F 445
THR B  20
GLN B  24
SER F 461
1.76A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2c3s 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A 149
VAL A 171
GLY A 138
GLY A 174
ILE A 106
1.28A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		6 / 12
GLY C 279
GLU C 281
GLY D 336
GLY C 276
VAL C 271
ILE C 293
1.61A17.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		4 / 8
GLN H   6
MET H 100
GLY H 104
GLY H  49
1.39A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 12
HIS W  80
PRO S  84
THR X  58
VAL X  57
LEU S 112
1.71A19.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
HIS A  70
SER A  67
ASN A  69
HIS A   2
SER A  63
1.39A20.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
GLY A  38
LEU A 112
GLY A  41
PHE A  20
VAL A  58
1.45A15.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
HIS A  70
SER A  67
ARG A 108
VAL A  75
ILE A  91
1.39A20.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
HIS A   2
SER A  67
ASN A  69
HIS A  72
ARG A 108
1.44A20.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
HIS A  70
SER A  67
ASN A  69
HIS A   2
THR A  68
1.35A20.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		4 / 8
GLN B  39
PHE B 230
GLY B  44
PRO B 176
1.32A22.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2gt8 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A 149
VAL A 171
GLY A 138
GLY A 174
ILE A 106
1.30A20.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr)		5 / 12
GLY A 300
GLU A 210
PHE A 329
VAL A 320
ILE A 305
1.49A23.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		6 / 12
GLY A 140
PHE A 134
LEU A 189
GLY A 156
GLY A 125
VAL A 148
1.53A23.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2kqv NSP3
(SARSr-CoV)		5 / 12
GLU A  65
THR A  90
GLY A  87
PRO A  26
ILE A  47
1.22A22.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
GLY A 129
GLU A 128
LEU A 142
THR A 144
GLY A 146
1.21A23.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
SER A 287
PRO A 262
THR A 285
LEU A 265
ILE A 280
1.71A20.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
PHE D 134
LEU D 189
GLY D 156
GLY D 125
VAL D 148
1.35A24.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
SER E 273
ASN E  74
PRO E 343
VAL E 275
ILE E 322
1.56A21.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2w2g NSP3
(SARSr-CoV)		5 / 12
GLU A 571
THR A 612
GLY A 609
PRO A 548
ILE A 560
1.35A21.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		2xyq NSP10
PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASP A 106
ASN B  85
PHE B  89
GLY B  88
GLY B  70
1.57A21.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
GLY A  71
LEU A 153
GLY A 148
GLY A 113
VAL A 118
1.34A22.38
SAH  A1293 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		2xyq NSP10
PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
HIS B  80
GLY A  77
SER A  74
GLY B  70
MET A  41
1.24A14.43
None
None
SAH  A1293 (-4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.73A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.72A21.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		2xyv NSP10
PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
HIS B  80
GLY A  77
SER A  74
GLY B  70
MET A  41
1.23A13.74
None
None
SAH  A1300 (-4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3bgf F26G19 FAB
(Mus
musculus)		5 / 12
SER L 176
PRO L 120
THR L 178
VAL L 132
ILE L 117
1.65A19.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		3bgf F26G19 FAB
(Mus
musculus)		5 / 12
SER B 182
PRO B 126
THR B 139
VAL B 138
ILE B 195
1.68A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3bgf F26G19 FAB
(Mus
musculus)		5 / 12
SER B 182
PRO B 126
THR B 139
VAL B 138
ILE B 195
1.74A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
HIS B 373
VAL B 318
LEU B 529
ILE B 544
SER B 411
1.35A16.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		3d0i SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLY F 480
PRO F 493
GLY F 391
VAL F 496
ILE F 397
1.05A17.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		3fzd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A 146
THR A 175
GLY A 179
GLY A  29
VAL A  13
1.32A21.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		3i6k BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 12
PHE F  62
GLN F   2
THR F  86
VAL F  85
ILE F  35
1.54A19.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		3r24 2'-O-METHYL
TRANSFERASE
NSP10 AND NSP11
(SARSr-CoV)		5 / 12
HIS B  80
GLY A  77
SER A  74
GLY B  70
MET A  41
1.28A17.98
None
None
SAM  A 302 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
GLY A  71
LEU A 153
GLY A 148
GLY A 113
VAL A 118
1.31A24.32
SAM  A 302 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.73A22.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE E 460
HIS E 445
THR A  20
GLN A  24
SER E 461
1.60A21.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE E 460
HIS E 445
THR A  20
GLN A  24
SER E 461
1.60A21.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE E 460
HIS E 445
THR A  20
GLN A  24
SER E 461
1.60A21.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		3sci ACE2
(Homo
sapiens)		4 / 8
GLN B 524
PHE B 525
GLY B 399
MET B 557
1.40A20.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 460
HIS F 445
THR B  20
GLN B  24
SER F 461
1.67A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 460
HIS F 445
THR B  20
GLN B  24
SER F 461
1.69A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 460
HIS F 445
THR B  20
GLN B  24
SER F 461
1.69A19.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		3scj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLY E 480
PRO E 493
GLY E 391
VAL E 496
ILE E 397
0.98A17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3scj ACE2
(Homo
sapiens)		5 / 12
HIS B 373
VAL B 318
LEU B 529
ILE B 544
SER B 411
1.36A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		3sck SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLY F 480
PRO F 493
GLY F 391
VAL F 496
ILE F 397
1.14A17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
GLN A 524
PHE A 525
GLY A 399
MET A 557
1.35A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
HIS B 373
VAL B 318
LEU B 529
ILE B 544
SER B 411
1.34A16.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		3vb5 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
HIS B  64
ARG B  76
GLN B  74
VAL B  68
SER B  62
1.76A20.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		4m0w REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		5 / 12
HIS A 273
SER A 112
PRO A 300
LEU A 254
ILE A 277
1.67A20.33
NHE  A 403 ( 3.6A)
NA  A 402 (-4.3A)
None
GOL  A 406 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		5 / 12
SER A 247
PHE A 312
THR A 308
VAL A 307
GLN A 213
1.55A18.89
None
None
None
PO4  A 404 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		5 / 12
SER A 247
PHE A 312
THR A 308
VAL A 307
GLN A 213
1.54A18.89
None
None
None
PO4  A 404 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		5 / 12
SER A 247
PHE A 312
THR A 308
VAL A 307
GLN A 213
1.52A18.89
None
None
None
PO4  A 404 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		5c8s NSP10
(SARSr-CoV)		5 / 12
ARG A  78
PHE A  68
GLY A  69
SER A  67
GLY A 109
1.68A15.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
ASN B 137
GLY B 123
PRO B 106
GLY B  93
MET B  58
1.51A21.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
SER B  28
PHE B  33
HIS B  19
THR B  25
VAL A  42
1.69A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		5c8t GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
SER B  28
PHE B  33
HIS B  19
THR B  25
VAL A  42
1.62A16.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8t GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
SER B  28
PHE B  33
HIS B  19
THR B  25
VAL A  42
1.59A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
ASN B 137
GLY B 123
PRO B 106
GLY B  93
MET B  58
1.49A21.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8t GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
SER B  28
PHE B  33
HIS B  19
THR B  25
VAL A  42
1.66A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 8
GLN B  65
MET B  62
PRO B  70
GLY B 202
MET B 241
1.70A21.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
GLN B  65
MET B  62
PRO B  70
GLY B 202
MET B 241
1.70A21.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
ASN A 137
GLY A 123
PRO A 106
GLY A  93
MET A  58
1.53A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 8
MET B  57
PHE B   8
GLY B   6
PRO B  24
1.43A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
ARG O  78
PHE O  68
GLY O  69
SER O  67
GLY O 109
1.79A16.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PHE A 219
VAL A 297
THR A 257
PRO A 293
ILE A 281
1.77A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A  69
MET A  17
GLY A  71
GLY A 143
1.79A17.75
None
None
DMS  A 403 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PHE A 219
GLU A 270
LEU A 205
GLY A 275
ILE A 281
1.68A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
VAL A 157
GLY A 149
PRO A  99
GLY A  15
1.69A15.93
None
None
None
None
DMS  A 403 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.54A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 149
PHE A 112
GLY A 143
GLY A 174
ILE A 136
1.65A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  15
GLU A  14
GLY A 149
GLY A 120
VAL A  36
1.59A15.93
DMS  A 403 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PHE A   8
THR A 292
GLY A 109
GLY A 149
ILE A 152
1.61A15.93
DMS  A 402 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  11
VAL A  68
GLY A  71
PHE A 159
VAL A 148
1.75A15.93
None
None
DMS  A 403 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5tl6 UBIQUITIN-LIKE
PROTEIN ISG15
(Homo
sapiens)		5 / 12
LEU A 124
PRO A 136
GLY A 138
VAL A  98
ILE A  84
1.25A13.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ASP C 727
ARG B 306
PHE B 305
ASN C 721
GLY B 580
1.64A17.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLY B 391
GLY B 434
PHE B 387
VAL B 337
ILE B 405
1.33A16.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.64A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.67A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.73A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ASP B1023
GLN B1088
GLY B 892
PRO B1051
GLY B1028
1.68A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
ASP B1023
GLN B1088
GLY B 892
PRO B1051
GLY B1028
1.68A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ARG C  99
GLN C 147
THR C 146
VAL C 172
SER C 169
1.42A10.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x59 S PROTEIN
(MERS-CoV)		5 / 12
SER B 268
PHE B 281
PRO B 145
VAL B 118
ILE B 256
1.67A9.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
HIS A1046
PRO A1035
VAL A 860
GLN A 786
ILE A 800
1.74A10.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
GLN B1088
GLY B 892
PRO B1051
GLY C 873
1.23A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
PRO C1035
THR C 863
VAL C 860
LEU C 788
ILE C 787
1.66A10.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
SER A 557
PHE A 467
ARG A 505
VAL A 555
SER A 524
1.71A9.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5x5f S PROTEIN
(MERS-CoV)		5 / 12
THR B 579
GLY C  61
GLY C 262
VAL B 403
ILE B 442
1.20A15.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
ASP B 537
GLN B 466
MET B 452
GLY B 462
GLY B 558
1.79A15.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		5x5f S PROTEIN
(MERS-CoV)		5 / 10
GLN A  72
PHE A  75
ASN A 114
GLY A  73
GLY A 340
1.74A15.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
SER B 268
PHE B 281
PRO B 145
VAL B 118
ILE B 256
1.64A9.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5x5f S PROTEIN
(MERS-CoV)		4 / 8
GLN A 466
MET A 452
GLY A 462
GLY A 558
1.13A15.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ARG A 232
PHE A 231
GLY A 104
GLY A 100
1.38A17.85
ARG  A 232 ( 0.6A)
PHE  A 231 ( 1.3A)
GLY  A 104 ( 0.0A)
GLY  A 100 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER C 380
ARG C 315
PRO C 565
GLN C 550
ILE C 319
1.61A10.71
SER  C 380 ( 0.0A)
ARG  C 315 ( 0.6A)
PRO  C 565 ( 1.1A)
GLN  C 550 ( 0.6A)
ILE  C 319 ( 0.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASP A 727
ASN A 746
GLY B 580
SER A 717
GLY A 726
1.60A17.85
ASP  A 727 ( 0.5A)
ASN  A 746 ( 0.6A)
GLY  B 580 ( 0.0A)
SER  A 717 ( 0.0A)
GLY  A 726 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER C 591
PRO C 282
VAL C 594
LEU C 597
ILE C 584
1.71A10.92
SER  C 591 ( 0.0A)
PRO  C 282 ( 1.1A)
VAL  C 594 ( 0.5A)
LEU  C 597 ( 0.6A)
ILE  C 584 ( 0.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
GLN A 902
PHE A 880
ASN B 691
GLY A 780
MET A1032
1.50A17.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
GLN B1036
MET B1032
PHE B1034
GLY B 862
1.25A17.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
GLY B1028
GLY A 867
PRO B 697
VAL B 893
ILE B 891
1.13A16.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6acg ACE2
(Homo
sapiens)		5 / 12
PRO D 583
THR D 519
GLN D 522
ILE D 407
SER D 411
1.64A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6acg ACE2
(Homo
sapiens)		5 / 12
PRO D 583
THR D 519
GLN D 522
ILE D 407
SER D 411
1.70A16.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6acj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE C 460
HIS C 445
THR D  20
GLN D  24
SER C 461
1.64A10.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER A 303
ASN C 746
VAL A 581
GLN A 301
SER C 717
1.64A10.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER C 703
THR C1048
VAL C1047
LEU C 898
ILE C 905
1.40A10.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASP A 649
ASN A 935
GLN A 931
GLY A 928
GLY A 298
1.67A17.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_D_CTCD1385_0
(TETX2 PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
ASP A 976
GLN C 984
ARG C 977
PHE C 952
SER C 985
1.61A16.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ASP A 976
GLN C 984
ARG C 977
PHE C 952
SER C 985
1.62A16.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
GLN A 895
PHE C1077
GLY C1075
GLY C1113
1.33A16.25
None
None
None
NAG  C1304 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ARG A 315
PRO A 565
GLN A 550
VAL A 562
ILE A 570
1.75A10.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
GLN B 902
PHE B 880
ASN A 691
GLY B 780
MET B1032
1.60A16.25
None
None
NAG  A1304 (-1.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLY C1067
GLY C1106
PHE C1071
VAL C1111
ILE C1114
1.31A15.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
GLN B1036
MET B1032
PHE B1034
GLY B 862
1.31A16.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
GLY C1067
GLY C1106
PHE C1071
VAL C1111
ILE C1114
1.23A16.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B 703
THR B1048
VAL B1047
LEU B 898
ILE B 905
1.54A10.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ASN A 118
THR A 236
VAL A 140
GLN A 147
SER A 169
1.63A10.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
ASP A 727
ARG C 306
PHE C 305
ASN A 721
GLY C 580
1.42A16.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_1
(TETRACYCLINE
DESTRUCTASE TET(50))		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
ASP C 454
ARG C 444
ARG C 441
LEU A 132
1.65A16.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_D_CTCD1385_0
(TETX2 PROTEIN)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
ASP A 976
GLN C 984
ARG C 977
PHE C 952
SER C 985
1.62A16.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ASP A 976
GLN C 984
ARG C 977
PHE C 952
SER C 985
1.62A16.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_1
(TETRACYCLINE
DESTRUCTASE TET(50))		6jyt HELICASE
(SARSr-CoV)		4 / 5
ASP B  56
ARG A  15
ARG A  22
LEU A  63
1.79A21.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6jyt HELICASE
(SARSr-CoV)		5 / 12
SER B 523
ARG B 567
GLN B 531
VAL B 510
SER B 513
1.68A13.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6jyt HELICASE
(SARSr-CoV)		5 / 12
ASP B 207
ASN B 516
ARG B 173
SER B 486
GLY B 206
1.71A21.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6jyt HELICASE
(SARSr-CoV)		4 / 8
MET B 378
GLY B 400
PRO B 284
GLY B 538
1.41A21.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.53A21.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.21A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.51A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		6 / 12
PHE E 400
LEU E 425
THR E 430
GLY E 431
VAL E 407
ILE E 402
1.53A21.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m18 ACE2
(Homo
sapiens)		5 / 12
HIS B 373
VAL B 318
LEU B 529
ILE B 544
SER B 411
1.34A13.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6m1d ACE2
(Homo
sapiens)		4 / 8
GLN D 524
PHE D 525
GLY D 399
MET D 557
1.37A18.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLU A 166
GLY C 302
GLY A 138
PHE A 112
VAL A 114
1.47A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL B 297
THR B 304
GLY B 302
PRO B 252
VAL B 261
1.53A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PHE C   8
THR C 292
GLY C 109
GLY C 149
ILE C 152
1.57A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PHE D   8
THR D 292
GLY D 109
GLY D 149
ILE D 152
1.54A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLN B  69
MET B  17
GLY B  71
GLY B 143
1.79A23.29
None
None
None
3WL  B 401 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLU B 166
GLY D 302
GLY B 138
PHE B 112
VAL B 114
1.45A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 195
THR A 169
GLY A 170
GLY A 183
VAL A 186
1.57A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.53A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
GLN A 815
MET A 756
PRO A 830
GLY A 596
1.73A17.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m71 NSP12
(SARS-CoV-2)		5 / 12
HIS A 572
ARG A 640
LEU A 308
ILE A 632
SER A 635
1.69A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
PRO A 296
GLY A 352
PHE A 652
VAL A 299
1.56A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 179
GLU A 180
VAL A 190
LEU A 316
ILE A 244
1.51A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL A 405
LEU B 128
PRO B 183
VAL B 159
ILE B 156
1.53A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ARG A 555
GLN A 444
THR A 409
VAL A 410
GLN A 408
1.56A12.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m71 NSP12
NSP7
(SARS-CoV-2)		5 / 12
PHE A 442
PRO A 412
VAL C  11
LEU C  55
ILE C  39
1.71A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
GLN C 902
PHE C 880
ASN A 691
GLY C 780
MET C1032
1.32A16.79
None
None
NAG  A1323 (-1.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
GLN C 902
PHE C 880
GLY C 780
MET C1032
1.26A16.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASN C 746
PRO A 617
THR A 302
VAL A 581
GLN A 301
1.71A10.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER L 181
THR L 183
VAL L 137
ILE L 122
SER H 144
1.65A22.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6nus NSP12
NSP8
(SARSr-CoV)		5 / 12
HIS A 362
THR A 344
VAL A 342
LEU B 103
ILE B 107
1.67A13.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.67A10.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.73A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ARG C 905
PHE C 888
GLY C 880
PRO C1053
1.22A16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE B 400
LEU B 425
THR B 430
GLY B 431
ILE B 402
1.15A15.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLN B 920
PHE B 898
ASN A 709
GLY B 799
MET B1050
1.47A16.67
None
None
NAG  A1304 (-1.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vw1 ACE2
(Homo
sapiens)		5 / 12
HIS B 373
VAL B 318
LEU B 529
ILE B 544
SER B 411
1.37A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vw1 ACE2
(Homo
sapiens)		5 / 12
GLY B 200
GLU B 197
GLY B 220
VAL B 226
ILE B 513
1.33A21.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vxs NSP3
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.36A
None
SO4  B 204 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vxs NSP3
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.31A
None
SO4  A 203 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLN C 920
PHE C 898
ASN B 709
GLY C 799
MET C1050
1.50A16.38
None
None
NAG  B1311 (-1.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS A 519
PHE A 565
ARG A 328
LEU A 552
ILE A 587
1.55A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE B 400
LEU B 425
GLY B 431
VAL B 407
ILE B 402
1.24A14.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS C 519
PHE C 565
ARG C 328
THR C 547
ILE C 587
1.75A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLN B 920
PHE B 898
GLY B 798
MET B1050
1.31A16.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS C 519
PHE C 565
ARG C 328
THR C 547
ILE C 587
1.75A10.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLN C 920
PHE C 898
GLY C 798
MET C1050
1.30A16.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLN B 920
PHE B 898
ASN A 709
GLY B 799
MET B1050
1.51A16.46
None
None
NAG  A1311 (-1.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER C 325
PHE C 541
ARG C 577
PRO C 579
THR C 531
1.74A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 377
VAL A 524
GLY A 526
GLY A 431
ILE A 434
1.24A14.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A1121
ARG B1091
THR B1105
VAL B1104
GLN B1113
1.77A10.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		6 / 12
GLY A 141
PHE A 135
LEU A 190
GLY A 157
GLY A 126
VAL A 149
1.48A25.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER A 274
ASN A  75
PRO A 344
VAL A 276
ILE A 323
1.78A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
LEU L  11
THR L 102
GLY L 101
PRO L  40
ILE L 106
1.75A14.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
GLN H   6
MET H 100
GLY H 104
GLY H  49
1.41A17.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
GLN L  79
ARG L  54
PHE L  62
GLY L  57
1.66A17.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  58
GLY C 381
PRO C 426
GLY C 413
1.27A17.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
THR H 110
VAL H 109
LEU H  80
ILE H  20
SER H   7
1.65A20.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
GLY H  49
LEU H  80
GLY H 106
GLY H  94
ILE H  51
1.78A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
THR H 107
GLY H   8
GLY H  24
PHE H  29
ILE H  34
1.25A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
PHE C 377
VAL C 524
GLY C 526
GLY C 431
ILE C 434
1.17A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
PHE C 400
LEU C 425
GLY C 431
VAL C 407
ILE C 402
1.36A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
GLN L  89
MET H  48
PRO L  44
GLY H 104
1.53A17.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
GLY C 404
GLY C 447
PHE C 400
VAL C 350
ILE C 418
1.42A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
GLN C 498
PHE C 497
GLY C 447
SER C 443
GLY C 504
1.64A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
GLN C 498
PHE C 497
GLY C 447
GLY C 504
1.76A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
PHE L  98
GLY L  99
GLY H  49
MET H 100
1.28A17.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		5 / 12
GLY C 413
VAL C 382
GLY H  97
VAL C 512
ILE C 410
1.75A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
PHE L 116
VAL L 163
THR L 172
PHE L 118
VAL H 181
1.65A14.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w4h NSP16
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.30A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w4h NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.41A15.45
None
None
SAM  A7102 ( 4.5A)
None
BDF  B4403 (-4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.37A
None
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w61 NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LEU A6893
THR A6880
GLY A6879
VAL A6916
ILE A7088
1.45A
None
None
SAM  A7104 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LEU A6887
THR A6891
GLY A6890
PHE A6954
ILE A6925
1.71A18.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.53A
None
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.77A
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.58A
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A 110
PHE A 294
PRO A 293
GLY A 251
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.52A
None
X77  A 401 ( 3.9A)
X77  A 401 (-4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  46
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.49A
None
None
None
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.64A
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.30A
None
None
None
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A  35
GLY A  85
PHE A 132
VAL A  96
1.79A18.73
None
None
None
AMP  A 201 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ARG C7077
GLY C6962
PRO C6860
GLY C7054
1.65A17.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.77A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
PHE D4321
GLY D4322
GLY D4362
1.75A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.24A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
LEU A6887
THR A6891
GLY A6890
PHE A6954
ILE A6925
1.67A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4322
MET C6839
1.42A15.45
None
None
SAM  C7105 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.33A15.45
None
None
SAM  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.44A15.45
None
None
SAM  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLY C6963
THR C6891
GLY C6890
PHE C6954
ILE C6925
1.78A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4323
MET C6839
1.74A15.45
None
SAM  C7105 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLU C7062
PRO C7013
GLY C7011
PHE C6985
ILE C6955
1.42A17.00
None
None
NA  C7103 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.75A19.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4323
MET C6839
1.29A15.45
None
None
SAM  C7105 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.76A15.45
None
SAM  A7102 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
LEU C6887
THR C6891
GLY C6890
PHE C6954
ILE C6925
1.73A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4322
MET C6839
1.61A15.45
None
SAM  C7105 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.60A15.45
None
SAM  A7102 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wcf NSP3
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.62A
MES  A 201 (-2.5A)
MES  A 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wcf NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.53A
MES  A 202 (-4.7A)
None
None
MES  A 201 (-3.2A)
MES  A 201 (-2.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wcf NSP3
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.26A
MES  A 202 (-3.4A)
None
None
MES  A 201 (-3.2A)
MES  A 201 (-2.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wey NSP3
(SARS-CoV-2)		5 / 12
GLY A 251
VAL A 359
LEU A 257
GLY A 334
PHE A 336
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 287
PHE F 286
PRO F 279
GLY F 284
ILE E 320
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE D 286
LEU C 331
GLY D 335
PRO C 309
ILE D 304
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE B 286
LEU A 331
GLY B 335
PRO A 309
ILE B 304
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE E 286
LEU F 331
GLY E 335
PRO F 309
ILE E 304
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY B 335
THR A 325
GLY A 328
PHE A 315
ILE A 320
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE F 286
LEU E 331
GLY F 335
GLY E 316
ILE F 304
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY E 321
LEU F 339
THR E 329
GLY E 328
GLY F 335
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY D 335
THR C 325
GLY C 328
PHE C 315
ILE C 320
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE B 286
LEU A 331
GLY B 335
GLY A 316
ILE B 304
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE A 286
LEU B 331
GLY A 335
GLY B 316
ILE A 304
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE F 286
LEU E 331
GLY F 335
PRO E 309
ILE F 304
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY E 335
THR F 325
GLY F 328
PHE F 315
ILE F 320
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 335
THR E 325
GLY E 328
PHE E 315
ILE E 320
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE E 286
LEU F 331
GLY E 335
GLY F 316
ILE E 304
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE D 286
LEU C 331
GLY D 335
GLY C 316
ILE D 304
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE C 286
LEU D 331
GLY C 335
PRO D 309
ILE C 304
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY A 335
THR B 325
GLY B 328
PHE B 315
ILE B 320
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE A 286
LEU B 331
GLY A 335
PRO B 309
ILE A 304
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE C 286
LEU D 331
GLY C 335
GLY D 316
ILE C 304
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		6 / 12
GLY E 278
GLU E 280
GLY F 335
GLY E 275
VAL E 270
ILE E 292
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.75A
None
SAH  A7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4322
MET C6839
1.56A
None
SAH  C7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4323
MET C6839
1.72A
None
SAH  C7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ARG C7077
GLY C6962
PRO C6860
GLY C7054
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
PHE D4321
GLY D4322
GLY D4362
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLU C7062
PRO C7013
GLY C7011
PHE C6985
ILE C6955
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4323
MET C6839
1.23A
None
None
SAH  C7102 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
GLY B4362
VAL A6876
LEU B4345
GLY B4322
PHE D4272
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4322
MET C6839
1.38A
None
None
SAH  C7102 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.57A
None
SAH  A7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.36A
None
None
SAH  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.26A
None
None
SAH  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS B  59
SER B 105
THR C 141
ILE C 146
SER C  78
1.76A21.78
 ZN  C 201 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS D  59
SER D 105
THR A 141
ILE A 146
SER A  78
1.74A
 ZN  A 201 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS D  59
SER D 105
THR A 141
ILE A 146
SER A  78
1.78A21.78
 ZN  A 201 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS B  59
SER B 105
THR C 141
ILE C 146
SER C  78
1.69A21.78
 ZN  C 201 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.76A
None
SFG  A7103 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.38A
None
None
SFG  A7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.60A
None
SFG  A7103 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLU C7062
PRO C7013
GLY C7011
PHE C6985
ILE C6955
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4323
MET C6839
1.74A
None
SFG  C7103 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.27A
None
None
SFG  A7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4322
MET C6839
1.59A
None
SFG  C7103 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ARG C7077
GLY C6962
PRO C6860
GLY C7054
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4322
MET C6839
1.40A
None
None
SFG  C7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
PHE D4321
GLY D4322
GLY D4362
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4323
MET C6839
1.26A
None
None
SFG  C7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		6 / 12
GLY B 141
PHE B 135
LEU B 190
GLY B 157
GLY B 126
VAL B 149
1.54A
None
None
None
None
ACT  B 408 (-4.2A)
ACT  B 408 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		6 / 12
GLY A 141
PHE A 135
LEU A 190
GLY A 157
GLY A 126
VAL A 149
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B 165
VAL B  10
GLY B  14
VAL B  85
ILE B  86
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.56A
None
U5G  A 401 ( 4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A 110
PHE A 294
PRO A 293
GLY A 251
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  46
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.49A
APR  B 201 (-3.7A)
None
None
APR  B 201 (-3.3A)
APR  B 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  46
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.50A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.0A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE C 132
GLY C 130
PRO C  98
GLY C 103
1.70A
APR  C 201 (-3.5A)
APR  C 201 (-3.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  47
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.51A
APR  C 201 (-4.1A)
None
None
APR  C 201 (-3.0A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.50A
APR  B 201 (-4.0A)
None
None
APR  B 201 (-3.3A)
APR  B 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  47
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.49A
APR  D 201 (-4.2A)
None
None
APR  D 201 (-3.2A)
APR  D 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE D 132
GLY D 130
PRO D  98
GLY D 103
1.75A
APR  D 201 (-3.5A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  46
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.50A
APR  D 201 (-3.8A)
None
None
APR  D 201 (-3.2A)
APR  D 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.77A
APR  B 201 (-3.6A)
APR  B 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.50A
APR  A 201 (-4.1A)
None
None
APR  A 201 (-3.5A)
APR  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.50A
APR  A 201 (-3.9A)
None
None
APR  A 201 (-3.5A)
APR  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.73A
APR  A 201 (-3.1A)
APR  A 201 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LEU A6893
THR A6880
GLY A6879
VAL A6916
ILE A7088
1.50A
None
None
SAH  A7101 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.61A
None
SAH  A7101 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.28A
None
None
SO4  A7109 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wq3 NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.48A
None
None
SO4  A7109 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.73A
None
SAH  A7101 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 12
HIS A  36
ARG D  80
THR D  89
LEU C  20
SER C  15
1.52A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
HIS A 272
SER A 111
PRO A 299
LEU A 253
ILE A 276
1.68A18.48
PO4  A 502 (-3.7A)
PO4  A 502 (-2.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PHE A 219
VAL A 297
THR A 257
PRO A 293
ILE A 281
1.77A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.53A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  11
VAL A  68
GLY A  71
PHE A 159
VAL A 148
1.75A16.59
None
None
DMS  A 406 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  15
GLU A  14
GLY A 149
GLY A 120
VAL A  36
1.61A16.59
DMS  A 406 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PHE A 219
GLU A 270
LEU A 205
GLY A 275
ILE A 281
1.72A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 149
PHE A 112
GLY A 143
GLY A 174
ILE A 136
1.65A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PHE A   8
THR A 292
GLY A 109
GLY A 149
ILE A 152
1.58A16.59
DMS  A 403 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
GLY E 447
PHE E 400
VAL E 350
ILE E 418
1.50A
DMS  E 902 (-3.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
GLN L  95
MET H  48
PRO L  50
GLY H 110
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 377
VAL A 524
GLY A 526
GLY A 431
ILE A 434
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  59
GLY E 381
PRO E 426
GLY E 413
1.08A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
GLN H 111
MET H   2
GLY H 110
GLY C  47
1.67A
None
None
None
1PE  C 301 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN L  95
ARG H  59
PRO H 105
GLY E 381
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
GLN C  95
MET B  48
PRO C  50
GLY B 110
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER L 182
PRO L 126
THR L 184
VAL L 138
ILE L 123
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
PHE L 104
GLY L 105
GLY H  49
MET H 106
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
GLN H   6
MET H 106
GLY H 110
GLY H  49
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
PHE C 104
GLY C 105
GLY B  49
MET B 106
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 400
LEU E 425
GLY E 431
VAL E 407
ILE E 402
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H 113
GLY H   8
GLY H  24
PHE H  29
ILE H  34
1.26A
None
MLI  B 304 ( 4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
GLN B 111
MET B   2
GLY B 110
GLY L  47
1.67A
None
None
None
1PE  L1603 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
PHE A 429
THR B 104
VAL A 382
LEU A 517
ILE C  34
1.60A17.89
None
None
DMS  A 905 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H 116
VAL H 115
LEU H  81
ILE H  20
SER H   7
1.58A18.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR B 113
GLY B   8
GLY B  24
PHE B  29
ILE B  34
1.25A
None
MLI  H 305 (-3.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yla LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER C 182
PRO C 126
THR C 184
VAL C 138
ILE C 123
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR B 116
VAL B 115
LEU B  81
ILE B  20
SER B   7
1.58A18.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG B  59
GLY A 381
PRO A 426
GLY A 413
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 400
LEU A 425
GLY A 431
VAL A 407
ILE A 402
1.39A
None
None
None
DMS  A 903 ( 4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
GLY E 447
PHE E 400
VAL E 350
ILE E 418
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN L  95
ARG H  59
PRO H 105
GLY E 381
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H 113
GLY H   8
GLY H  24
PHE H  29
ILE H  34
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
GLN H   6
MET H 106
GLY H 110
GLY H  49
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
PHE L 104
GLY L 105
GLY H  49
MET H 106
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 12
THR H 116
VAL H 115
LEU H  81
ILE H  20
SER H   7
1.58A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
GLN L  95
MET H  48
PRO L  50
GLY H 110
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  59
GLY E 381
PRO E 426
GLY E 413
1.12A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 400
LEU E 425
GLY E 431
VAL E 407
ILE E 402
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
GLY E 447
PHE E 400
VAL E 350
ILE E 418
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
GLN H   6
MET H 106
GLY H 110
GLY H  49
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A 404
GLY A 447
PHE A 400
VAL A 350
ILE A 418
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 8
GLN L  95
MET H  48
PRO L  50
GLY H 110
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN C  95
ARG B  59
PRO B 105
GLY A 381
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 8
GLN C  95
MET B  48
PRO C  50
GLY B 110
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
THR H 113
GLY H   8
GLY H  24
PHE H  29
ILE H  34
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
THR B 113
GLY B   8
GLY B  24
PHE B  29
ILE B  34
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  59
GLY E 381
PRO E 426
GLY E 413
1.09A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG B  59
GLY A 381
PRO A 426
GLY A 413
1.08A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN L  95
ARG H  59
PRO H 105
GLY E 381
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
SER L 182
PRO L 126
THR L 184
VAL L 138
ILE L 123
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 8
PHE C 104
GLY C 105
GLY B  49
MET B 106
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
GLN B   6
MET B 106
GLY B 110
GLY B  49
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 377
VAL A 524
GLY A 526
GLY A 431
ILE A 434
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 400
LEU A 425
GLY A 431
VAL A 407
ILE A 402
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 8
PHE L 104
GLY L 105
GLY H  49
MET H 106
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
THR H 116
VAL H 115
LEU H  81
ILE H  20
SER H   7
1.57A18.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 400
LEU E 425
GLY E 431
VAL E 407
ILE E 402
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 12
THR B 116
VAL B 115
LEU B  81
ILE B  20
SER B   7
1.57A18.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yor IGG L CHAIN
(Homo
sapiens)		5 / 12
SER C 182
PRO C 126
THR C 184
VAL C 138
ILE C 123
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.57A
None
PK8  A 401 ( 3.6A)
PK8  A 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
GLN A  69
MET A  17
GLY A  71
GLY A 143
1.77A
None
None
None
PK8  A 401 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  47
VAL E 155
LEU E  53
GLY E 130
PHE E 132
1.36A
EPE  E 202 (-4.3A)
EDO  E 205 ( 4.2A)
None
EPE  E 202 ( 4.5A)
EPE  E 202 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  47
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.41A
EDO  D 206 (-4.5A)
EDO  D 208 ( 4.2A)
None
EDO  D 205 ( 4.9A)
EDO  D 205 ( 3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.33A
None
None
None
EDO  A 202 ( 4.4A)
EDO  A 202 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.50A
APR  A 201 (-4.2A)
APR  A 201 ( 4.8A)
None
APR  A 201 ( 3.2A)
APR  A 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.53A
APR  B 201 (-3.6A)
None
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE E 132
GLY E 130
PRO E  98
GLY E 103
1.68A
APR  E 201 (-3.5A)
APR  E 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE D 132
GLY D 130
PRO D  98
GLY D 103
1.72A
APR  D 201 (-3.3A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  46
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.50A
APR  D 201 (-3.8A)
None
None
APR  D 201 (-3.2A)
APR  D 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.74A
APR  B 201 (-3.5A)
APR  B 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.71A
APR  A 201 (-3.7A)
APR  A 201 ( 3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  47
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.56A
APR  C 201 (-4.3A)
APR  C 201 ( 4.9A)
None
APR  C 201 (-3.2A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  47
VAL E 155
LEU E  53
GLY E 130
PHE E 132
1.56A
APR  E 201 (-4.4A)
APR  E 201 ( 4.9A)
None
APR  E 201 (-3.2A)
APR  E 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE C 132
GLY C 130
PRO C  98
GLY C 103
1.72A
APR  C 201 (-3.5A)
APR  C 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  46
VAL E 155
LEU E  53
GLY E 130
PHE E 132
1.47A
APR  E 201 (-3.9A)
APR  E 201 ( 4.9A)
None
APR  E 201 (-3.2A)
APR  E 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.53A
APR  A 201 (-4.1A)
APR  A 201 ( 4.8A)
None
APR  A 201 ( 3.2A)
APR  A 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  46
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.51A
APR  C 201 (-4.3A)
APR  C 201 ( 4.9A)
None
APR  C 201 (-3.2A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  46
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.56A
EDO  B 202 (-3.9A)
None
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  47
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.39A
MES  C 201 ( 4.9A)
EDO  C 206 ( 4.2A)
None
MES  C 201 (-3.3A)
MES  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY A  47
GLU B 170
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.40A
MES  A 201 ( 4.8A)
None
None
None
MES  A 201 (-3.1A)
MES  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY A  46
GLU B 170
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.57A
MES  A 201 ( 4.9A)
None
None
None
MES  A 201 (-3.1A)
MES  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.65A
MES  A 201 (-3.5A)
MES  A 201 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE C 132
GLY C 130
PRO C  98
GLY C 103
1.67A
MES  C 201 (-3.6A)
MES  C 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.41A
None
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
ARG A 555
GLN A 444
THR A 409
VAL A 410
GLN A 408
1.62A12.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
PHE A  45
HIS A 133
THR A 141
LEU A 247
ILE A 244
1.75A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
NSP7
(SARS-CoV-2)		5 / 12
PHE A 442
PRO A 412
VAL C  11
LEU C  55
ILE C  39
1.67A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
PRO A 296
GLY A 352
PHE A 652
VAL A 299
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
HIS A 872
ASN A 874
HIS A 816
ARG A 836
PRO A 832
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
HIS A 362
THR A 344
VAL A 342
LEU B 103
ILE B 107
1.79A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 179
GLU A 180
VAL A 190
LEU A 316
ILE A 244
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ARG A 555
GLN A 444
THR A 409
VAL A 410
GLN A 408
1.53A12.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 179
GLU A 180
VAL A 190
LEU A 316
ILE A 244
1.53A
None